Addendum
Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12
Report documents
-
Addendum
Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12
Dossier assessment
Indication:
Treatment-naive adults with intermediate or poor-risk advanced renal cell carcinoma
Result of dossier assessment:
Conclusion of dossier assessments A19-11 and A19-12 unchanged
Additional information
Federal Joint Committee (G-BA)
2019-08-15 A G-BA decision was published.
Project details
- Project no.
- A19-54
- Commission
- Commission awarded on 24.06.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed